LINCOLN · Lincoln Pharmaceuticals Ltd · Biotechnology & Drugs
LINCOLN · Lincoln Pharmaceuticals Ltd · Biotechnology & Drugs
As of 05 Nov close
52-week range
33.4% below 52-week high
52-week range: as of 05 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 15 Sep 2026 · the company's own latest record is 52 days old
Revenue (latest Q)
₹177 Cr
Revenue YoY
PAT YoY
+30.9%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
1.6
P/S (TTM)
1.8
Sector P/E
36.3
Dividend yield
+0.3%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| LINCOLN (this stock) | 13 | 1.6 | +13.9% | +12.7% | 0.01 | +0.3% |
| Sun Pharmaceutical Industries | 38.4 | 5.6 | +19.1% | +14.2% | 0.47 | +0.8% |
| Divi's Laboratories | 59.7 | 14.5 | +26.1% | +17.4% | 0 | +0.3% |
| Torrent Pharmaceuticals | 72.7 | 19.2 | +15.3% | +27.1% | 141.16 | +0.8% |
Promoter
stable
FII
falling 1q
MF
Not available from data source
Insider trades
No insider trades in the last 12 months.
Bulk/block deals
| canonicalSymbol | date | buy quantity | buyer count | deal strength | deal types present |
|---|---|---|---|---|---|
| LINCOLN | 2026-04-29 | 318402 | 2 | WEAK | BULK |
News timeline
No related news.
Concalls & investor presentations
AI-generatedNo concall transcripts or investor presentations recorded yet.
AI Summary of Annual Report
AI-generatedLincoln Pharmaceuticals Limited's annual report for FY2025-26 highlights the company's commitment to responsible growth, emphasizing quality, access, affordability, and sustainability. The report outlines the company's global economic context, noting challenges from geopolitical conflicts and trade frictions affecting logistics and costs. India's economic performance is highlighted as a positive factor, with strong growth and supportive monetary policies. The company discusses its strategic focus on innovation, R&D, and global market diversification to mitigate risks and sustain growth. It also emphasizes corporate governance, ethical practices, and stakeholder engagement.
- Commitment to responsible growth with a focus on quality, access, affordability, and sustainability.
- Strategic emphasis on innovation, R&D, and global market diversification.
- India's economic performance as a key growth driver with supportive monetary policies.
- Corporate governance and ethical practices as core values.
- Risk management strategies including diversification of export markets and investment in talent and IT security.
Key takeaway: Lincoln Pharmaceuticals Limited prioritizes responsible growth, innovation, and robust risk management strategies to navigate global challenges and leverage India's economic strengths.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
Regulatory Action (2 items)
Items of these kinds are disclosed in the filings. This is a count of disclosed items. It is not a finding about the company and its cause has not been independently established.
Regulatory Action
2 occurrencesRecent (last 12 months)
The company received cautionary mails from BSE and NSE on March 28, 2025, regarding non-compliance with SEBI LODR.
Earlier (1-3 years ago)
The company received cautionary mails from BSE and NSE on March 28, 2025, for non-compliance with the prescribed timelines for submission under SEBI LODR.
Routine disclosures
Contingent Liability
1 occurrenceRecent (last 12 months)
The company has contingent liabilities including bank guarantees and pending litigation, with amounts not quantifiable, and expects favorable judgments.